Wójtowicz Katarzyna, Przepiorka Lukasz, Kujawski Sławomir, Marchel Andrzej, Kunert Przemysław
Department of Neurosurgery, Medical University of Warsaw, 02-091 Warsaw, Poland.
Department of Exercise Physiology and Functional Anatomy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-077 Bydgoszcz, Poland.
J Clin Med. 2023 Jul 11;12(14):4619. doi: 10.3390/jcm12144619.
Although anterior communicating artery (AComA) unruptured intracranial aneurysms (UIAs) comprise one of the largest aneurysm subgroups, their complex adjacent neurovasculature and increased risk of rupture impede optimal management. In the present study, we analyzed the results of our diverse strategy in AComA UIAs with the additional goal of assessing the risk of treatment and the incidence of hemorrhage. We analyzed 131 patients, of which each was assessed by a multidisciplinary neurovascular team and assigned to observation (45.8%), endovascular treatment (34.4%) or microsurgery (19.8%). Median aneurysm sizes were 3, 7.2 and 7.75 mm, respectively. In the observation group, four (7.1%) aneurysms (initially <5 mm) grew over a median time of 63.5 months and were treated endovascularly. We found that fewer patients in the observation group were smokers ( = 0.021). The aneurysm size ratio was different between the combined treatment versus the observation group ( < 0.0001). Noteworthily, there were no hemorrhages in the observational group. Mortality for all patients with available follow-up was 2.4% (3/124) and permanent morbidity was 1.6% (2/124) over a mean follow-up of 64.2 months. These compelling rates refer to a high-risk group with potentially devastating consequences in which we have decreased the annual risk of hemorrhage to 0.14%.
尽管前交通动脉(AComA)未破裂颅内动脉瘤(UIAs)是最大的动脉瘤亚组之一,但其复杂的相邻神经血管结构以及破裂风险增加阻碍了最佳治疗。在本研究中,我们分析了我们在AComA UIAs中采用的多种策略的结果,另外还有评估治疗风险和出血发生率的目标。我们分析了131例患者,每例患者均由多学科神经血管团队进行评估,并被分配至观察(45.8%)、血管内治疗(34.4%)或显微手术(19.8%)。动脉瘤的中位大小分别为3、7.2和7.75毫米。在观察组中,4例(7.1%)动脉瘤(初始<5毫米)在中位时间63.5个月内增大,并接受了血管内治疗。我们发现观察组中吸烟的患者较少(P = 0.021)。联合治疗组与观察组之间的动脉瘤大小比不同(P < 0.0001)。值得注意的是,观察组中没有出血情况。在平均64.2个月的随访期内,所有有可用随访数据的患者的死亡率为2.4%(3/124),永久性致残率为1.6%(2/124)。这些令人信服的比率适用于一个具有潜在毁灭性后果的高危组,我们已将该组每年的出血风险降至0.14%。